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I read ‘‘Use of the fluocinolone acetonide
intravitreal implant for the treatment of
noninfectious posterior uveitis (NIPU): 3-year
results of a randomized clinical trial in a
predominantly Asian population’’ (December
2014) [1]. This article is certainly of interest,
especially regarding the effectiveness of 0.59
and 2.1 mg doses of fluocinolone acetonide
(FAc) intravitreal implant for the treatment of
NIPU in a predominantly Asian patient
population.
However, I would like to make sure that your
readership does not confuse the FAc intravitreal
implant reported by Sangwanet al. (i.e., Retisert;
contains 0.59 mg of FAc) with the FAc implant
(ILUVIEN; contains 190 lg of FAc) licenced in
Europe for the indication ‘… for the treatment
of vision impairment associated with chronic
diabetic macular edema (DMO), considered
insufficiently responsive to available therapies
[2]’. This letter highlights the key differences
between Retisert and ILUVIEN.
These products are licenced by different
manufacturers. Retisert is manufactured by
Bausch & Lomb (Rochester, NY, USA) and
ILUVIEN is manufactured by Alimera Sciences
(based in Atlanta, Georgia, USA and Aldershot,
UK).
These products contain and deliver different
amounts of FAc. Retisert delivers 0.59 mg of
FAc with an initial rate of 0.6 mg of FAc per
day, which decreases over the 1st month to a
steady rate of 0.3–0.4 lg FAc per day [3].
ILUVIEN contains a total of 190 lg of FAc with
an average daily release of 0.2 lg of FAc per day
[2, 4].
These products release FAc for different amounts
of time. Retisert releases 0.3–0.4 lg FAc per day
for between 30 [3, 4] and 36 months [1]. In
contrast, ILUVIEN releases 0.2 lg FAc per day
for up to 36 months [4].
These products are administered differently.
Retisert is surgically implanted into the
posterior segment of the affected eye through
a pars plana incision. ILUVIEN is an intravitreal
implant that is inserted using a 25-gage needle
into the vitreous cavity in the posterior eye with
the optimal placement being inferior to the
optic disc and posterior to the equator [2].
These products have different indications. In
Europe, Retisert is not licensed whereas
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ILUVIEN is licensed and indicated for ‘‘… the
treatment of vision impairment associated with
chronic diabetic macular oedema, considered
insufficiently responsive to available therapies.’’
[2]. In the USA, Retisert is indicated for ‘‘…the
treatment of chronic noninfectious uveitis
affecting the posterior segment of the eye’’ [3]
and not for DMO. The indication for ILUVIEN
in the USA is for ‘‘…or the treatment of diabetic
macular edema in patients who have been
previously treated with a course of
corticosteroids and did not have a clinically
significant rise in intraocular pressure’’ [5].
I would like to highlight that ILUVIEN was
designed to improve on the performance of
Retisert to deliver the lowest dose of
corticosteroid, currently under investigation,
to the retina [6]. Furthermore, I would like to
point the reader in the direction of Kane et al.
[6] which explains the development history and
characteristics of Retisert and ILUVIEN. The
paper by Campochiaro et al. [4] is also very
helpful as it compares the aqueous levels of FAc
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